^
Association details:
| Biomarker: | KRAS G12D |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | beroterkib anhydrous (ASTX029) (ERK2 inhibitor, ERK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors.
Published date:
05/26/2022
Excerpt:
ASTX029 was administered orally daily on a continuous basis in 21-day cycles...Four subjects had a partial response, including KRAS-G12A BRAF-D549N non-small cell lung cancer (NSCLC; Phase 1A: 120 mg treated 20.0 months); KRAS-G12D pancreatic cancer (Phase 1A: 200 mg treated 2.1 months); KRAS-G13D NSCLC (Phase 1B; treated 10.6 months); KRAS-G12S NSCLC (Phase 1B; treated 10.4 months and ongoing).
DOI:
10.1200/JCO.2022.40.16_suppl.9085
Source:
Title:
CT108 - A first-in-human, Phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors
Published date:
03/10/2021
Excerpt:
ASTX029 was administered orally daily...Two subjects, one with KRAS-G12A and BRAF-D549N non-small cell lung cancer (120 mg) and one with KRAS-G12D metastatic pancreatic cancer (200 mg), achieved partial responses.
